Business
Regen BioPharma, Inc. Receives New Preliminary HemaXellerate Clinical Data on Bone Marrow Suppression from Pan Am Cancer Treatment Center
Regen BioPharma, Inc. Receives New Preliminary HemaXellerate Clinical Data on Bone Marrow Suppression from Pan Am Cancer Treatment Center.
About this update from Regen Biopharma, Inc.
[{"type":"text","content":"\n\n\n\nRegen BioPharma, Inc. Receives New Preliminary HemaXellerate Clinical Data on Bone Marrow Suppression from Pan Am Cancer Treatment Center\n\n\n\n\n\nRegen BioPharma, Inc. Receives New Preliminary HemaXellerate Clinical Data on Bone Marrow Suppression from Pan Am Cancer Treatment Center\nPR Newswire\nSAN DIEGO, August 16, 2016\n\n\n\nSAN DIEGO, August 16, 2016 /PRNewswire/ --\n\nRegen BioPharma, Inc., (OTCQB: RGBP) and (OTCQB: RGBPP) announced today that the Pan Am Cancer Treatment Center in Tijuana, Mexico, which has a non-exclusive license to test HemaXellerate in a first-in-human proof of concept study, presented new interim clinical data on their first 5 patients. Beginning in March 2016, 5 patients with chemotherapy-induced bone marrow suppression were treated with HemaXellerate and initial 1 month follow up data were provided. Pan Am Cancer Treatment Center has now provided 3 month follow up data in these same patients. The primary endpoint of the study is safety and the secondary endpoint is effectiveness.\n\nRegarding safety, none of the 5 patients had any adverse events. In other words, all of the patients tolerated HemaXellerate with no side-effects. Effectiveness was measured by taking blood tests of the patients 1 month and 3 months post-HemaXellerate treatment and measuring the levels of blood cells, particularly immune cells, circulating in their blood. As previously presented, at 1 month post-HemaXellerate treatment, 2 patients (40%) had a dramatic increase in their circulating white blood cells to levels even above the normal range and 2 other patients had their white blood cells return to the normal range.\n\nIn the latest data presented, the patients who apparently benefited after one month maintained their high levels of white blood cells and all 5 patients had increased numbers of white blood cells after 3 months as compared to after 1 month. In addition, 4 out of 5 patients had increased numbers of red blood cells and all 5 patients had increased numbers of platelets 3 months after treatment as compared to after 1 month.\n\n\"These data are interesting. While there is no control group which would help us determine if this promising data are a consequence of HemaXellerate treatment, the apparent profound and sustained increase in white blood cell counts suggests that HemaXellerate may have some ef...